<DOC>
	<DOCNO>NCT01273389</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety CNTO 136 administer intravenously patient active , International Society Nephrology/Renal Pathology Society Class III IV Lupus Nephritis ( LN ) .</brief_summary>
	<brief_title>An Efficacy Safety Study CNTO 136 Patients With Active Lupus Nephritis</brief_title>
	<detailed_description>This multicenter ( study conduct multiple site ) , randomize ( study medication assign chance ) , double-blind ( neither investigator patient know treatment patient receives ) , placebo-controlled ( inactive substance compare study medication test whether study medication real effect clinical study ) , parallel group ( group patient treat time ) study CNTO 136 patient active LN . The study consist 3 phase , ie , screen phase ( approximately 8 week prior randomization ) , treatment phase ( 24 week ) , follow phase ( week 40 ) . An 8 week run-in period use establish stability baseline renal parameter prior randomization first study medication . The eligible patient randomly assign 5:1 ratio receive 1 2 treatment group treatment phase : Group 1 : CNTO 136 10 mg/kg intravenous ( IV ) , Weeks 0 , 4 , 8 , 12 , 16 , 20 , 24 ; Group 2 : Placebo infusion , IV , Weeks 0 , 4 , 8 , 12 , 16 , 20 , 24 . Patients ' medication regimen LN may adjust Week 24 visit afterwards . Safety evaluation adverse event , infection , clinical laboratory test , electrocardiogram , vital sign , physical examination skin evaluation perform throughout study . The follow phase end study Week 40 visit last patient randomize , , event last patient randomize withdraws study early , end study define date last visit last patient participate study .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<criteria>Diagnosis Systemic lupus erythematosus ( SLE ) , biopsyproven International Society Nephrology/Renal Pathology Society Class III IV lupus glomerulonephritis within approximately 14 month prior randomization Persistently active nephritis define , proteinuria great 0.5g/day determine measurement total urine protein le 0.5 g/24 hour urine Protein/Creatinine ( P/C ) ratio great 0.5 ( mg/mg ) time collection 12 hour , 2 month prior first administration study medication observe least 2 visit conduct 1 week apart screen period Active Class III Class IV lupus nephritis determine recent biopsy within approximately 6 month prior screen least 1 follow 3 criterion : hematuria ( blood urine ) , antiDNA positivity , low C3 C4 complement level Stable immunosuppression least 9 week prior first administration study medication consist MMF 13 g/day ( equivalent dose MPA ) with/without corticosteroid prednisone equivalent 20 mg/day , azathioprine 13 mg/kg/day with/without corticosteroid prednisone equivalent 20 mg/day Stable dose angiotensinconverting enzyme ( ACE ) inhibitor/angiotensin II receptor blocker ( ARB ) least 9 week prior first administration study medication If use oral corticosteroid , must stable dose equivalent 20 mg/day less prednisone least 9 week prior first administration study medication Cyclophosphamide use within 3 month randomization Bcell depletion therapy within 6 month screen , evidence persistent Bcell depletion time screen Greater 50 percent glomerular sclerosis renal biopsy Serum creatinine &gt; 2.5 mg/dL ( SI : &gt; 177 µmol/L ) White blood cell count &lt; 3.5 x 10^3 cells/µL ( SI : &lt; 3.5 x 10^9 cells/L ) neutrophils &lt; 1.96 x 10^3 cells/µL ( SI : &lt; 1.96 x 10^9 cells/L ) Platelets &lt; 140 x 103 cells/ µL ( SI : &lt; 140 x 10^9 cells/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lupus nephritis</keyword>
	<keyword>CNTO 136</keyword>
	<keyword>Sirukumab</keyword>
	<keyword>Kidney disease</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Glomerulonephritis</keyword>
</DOC>